{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Remote-Central-Monitoring-Procedures”
},
“headline”: “SOP for Remote and Central Monitoring Procedures in Clinical Trials”,
“description”: “This SOP outlines standardized processes for conducting remote and central monitoring in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP guidance while supporting risk-based monitoring models.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 23/12/2025
Standard Operating Procedure for Remote/Central Monitoring Procedures
| Department | Clinical Operations / Monitoring |
| SOP No. | CR/OPS/065/2025 |
| Supersedes | NA |
| Page No. | 1 of 34 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to establish standardized procedures for conducting remote and central monitoring of clinical trials. These approaches complement or replace traditional onsite monitoring in
Scope
This SOP applies to sponsors, CROs, CRAs, data managers, and QA officers engaged in clinical trial oversight. It covers remote monitoring (site-level review conducted offsite) and central monitoring (system-level oversight using aggregated data). It applies to EDC, CDMS, eTMF, safety databases, and laboratory systems used for clinical data management.
Responsibilities
- Sponsor: Approves remote/central monitoring strategies and ensures compliance with ICH GCP.
- Clinical Operations Manager: Defines monitoring methods, visit schedules, and escalation triggers.
- CRA/Monitor: Conducts remote monitoring visits, documents findings, and communicates with sites.
- Central Monitoring Team: Performs centralized data review, trend analysis, and signal detection.
- PI: Provides secure remote access to subject records and responds to monitoring queries.
- QA Officer: Verifies monitoring documentation and inspects RBM implementation.
Accountability
The sponsor is accountable for ensuring remote and central monitoring activities are conducted per protocol, GCP, and regulatory requirements. Clinical Operations is accountable for execution, while QA ensures oversight and compliance.
Procedure
1. Planning Remote/Central Monitoring
Conduct risk assessment to determine feasibility of remote or central monitoring.
Define critical data elements and processes requiring remote oversight.
Document monitoring strategy in Monitoring Plan (Annexure-1).
2. Remote Monitoring Preparation
Notify site at least 2 weeks prior to scheduled remote monitoring session.
Ensure secure remote access is granted through validated portals.
Prepare Remote Monitoring Checklist (Annexure-2).
3. Conduct of Remote Monitoring
CRA reviews eCRFs, informed consent scans, drug accountability records, and training logs remotely.
Conduct video/teleconferences with PI and staff to address open queries.
Document discrepancies in Remote Monitoring Report (Annexure-3).
4. Central Monitoring Activities
Aggregate site data into centralized dashboards.
Analyze KRIs (e.g., SAE reporting delays, outlier data trends, high protocol deviations).
Generate Central Monitoring Review Report (Annexure-4).
5. Documentation and Reporting
File remote and central monitoring reports in TMF.
Communicate findings to site and sponsor within 7 working days.
Initiate CAPA for significant findings (Annexure-5).
6. Frequency
Remote monitoring conducted every 4–6 weeks or as per risk profile.
Central monitoring performed continuously or monthly depending on trial design.
7. Escalation
Critical findings such as fraudulent data, subject safety concerns, or repeated non-compliance must be escalated within 24 hours.
Record in Escalation Log (Annexure-6).
8. Archiving
Archive monitoring reports, dashboards, checklists, and CAPA documentation in TMF/ISF.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- CRA: Clinical Research Associate
- CRO: Clinical Research Organization
- QA: Quality Assurance
- TMF: Trial Master File
- ISF: Investigator Site File
- RBM: Risk-Based Monitoring
- KRI: Key Risk Indicator
- SDV: Source Data Verification
Documents
- Monitoring Plan (Annexure-1)
- Remote Monitoring Checklist (Annexure-2)
- Remote Monitoring Report (Annexure-3)
- Central Monitoring Review Report (Annexure-4)
- CAPA Log (Annexure-5)
- Escalation Log (Annexure-6)
References
- ICH E6(R2) – Good Clinical Practice
- FDA – Guidance on Risk-Based Monitoring
- EMA – Reflection Paper on RBM
- CDSCO – Clinical Monitoring Guidelines
- WHO – Remote Monitoring Practices
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, CRA |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: Monitoring Plan
| Trial | Strategy | Frequency | Approved By |
|---|---|---|---|
| Trial A | Hybrid (Remote + Central) | Every 6 weeks | Sponsor |
| Trial B | Centralized Only | Monthly | QA Officer |
Annexure-2: Remote Monitoring Checklist
| Item | Status | Remarks |
|---|---|---|
| Consent Forms Uploaded | Complete | All subjects available |
| Drug Accountability Logs | Incomplete | One missing entry |
Annexure-3: Remote Monitoring Report
| Date | Site | Findings | Deviation | Corrective Action |
|---|---|---|---|---|
| 15/09/2025 | Site 001 | Delayed data entry | 2 | Site retrained |
| 17/09/2025 | Site 002 | Consent page not uploaded | 1 | Corrected by PI |
Annexure-4: Central Monitoring Review Report
| Date | KRI Monitored | Result | Action Taken | Reviewed By |
|---|---|---|---|---|
| 18/09/2025 | SAE Reporting Timeliness | Delayed at 2 sites | Escalated | Central Monitor |
| 19/09/2025 | Protocol Deviations | Above QTL at 1 site | Triggered CAPA | QA Officer |
Annexure-5: CAPA Log
| Date | Issue | CAPA | Responsible | Status |
|---|---|---|---|---|
| 20/09/2025 | Consent upload missing | Training + system alert | PI | Open |
| 21/09/2025 | Data entry delay | Retraining | CRA | Closed |
Annexure-6: Escalation Log
| Date | Issue | Escalated To | Resolution | Closed By |
|---|---|---|---|---|
| 22/09/2025 | Fraudulent data suspicion | Sponsor | Investigation initiated | QA Officer |
| 23/09/2025 | Serious safety concern | Regulator | Site suspended | Sponsor |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Operations |
For more SOPs visit: Pharma SOP